Skip to content

Hereditary syndromes and genetics

TL;DR — A clinically important minority of colorectal adenocarcinomas reflects inherited susceptibility, but no single screen captures it. Universal MMR/MSI tumor testing finds Lynch-associated biology and predicts immunotherapy response, yet tumor screening alone misses non-MMR syndromes and even some Lynch cases (Pearlman 2021, PMID 34250417). Unselected germline-panel studies report pathogenic variants in roughly 14–16%, while 38% may receive a variant of uncertain significance on broad commercial testing (Uson 2022, PMID 33857637; Coughlin 2022, PMID 36370464). Lynch syndrome requires gene-specific surveillance rather than one pooled risk estimate; APC-associated FAP requires lifelong colorectal and extracolonic management, often including prophylactic surgery (Peltomäki 2023, PMID 36706841; Half 2009, PMID 19822006). The central implementation failure is not assay sensitivity alone but the handoff from tumor result to counseling, germline confirmation, cascade testing and sustained family surveillance.

Who should trigger hereditary evaluation?

Trigger What it enriches for Why it is insufficient alone
dMMR/MSI-high tumor Lynch syndrome and sporadic MLH1 methylation Some hereditary syndromes are MMR-proficient
Diagnosis at young age Multiple germline syndromes Many carriers present later; most young cases are not monogenic
Multiple colorectal primaries Lynch/polyposis/field susceptibility Can also be sporadic
High adenoma burden APC, MUTYH, POLE/POLD1 and other polyposis Attenuated syndromes may have modest counts
Hamartomatous polyps STK11, SMAD4/BMPR1A, PTEN pathways Pathology classification and mosaicism complicate inference
Family history Shared inherited susceptibility Small families, sex-specific cancers and missing data reduce sensitivity
Characteristic extracolonic cancer Syndrome-specific spectrum Cancer spectra overlap
Unselected CRC Broad panel detects unexpected variants Cost, VUS and low cascade completion

The safest model combines universal tumor testing, structured family/polyp history and a low threshold for germline testing rather than making these competing strategies.

Lynch syndrome

Lynch syndrome results from a germline pathogenic variant affecting MLH1, MSH2, MSH6 or PMS2, or EPCAM deletion causing MSH2 silencing. Tumors develop MMR deficiency, insertion/deletion errors and a frameshift-rich mutational landscape (Peltomäki 2023, PMID 36706841).

Gene-specific heterogeneity

Gene/pathway General pattern Management implication
MLH1 Higher colorectal penetrance, both sexes Intensive colon surveillance; broad extracolonic counseling
MSH2/EPCAM Colorectal plus urothelial and other extracolonic risk Gene-specific extracolonic awareness
MSH6 Later/lower colorectal penetrance than MLH1/MSH2 on average; high endometrial risk Avoid pooled “Lynch risk” estimates
PMS2 Lower average colorectal penetrance Surveillance remains indicated but interval evidence is evolving

Prospective Lynch Syndrome Database data show cancer incidence and mortality vary by gene, age and sex even under surveillance (Møller 2017, PMID 26657901; Dominguez-Valentin 2023, PMID 37181409). This variation makes syndrome-wide lifetime-risk percentages misleading for an individual carrier.

Tumor-first workflow

IHC result Frequent cause Reflex step
MLH1/PMS2 loss MLH1 methylation, BRAF-associated sporadic tumor or germline MLH1 BRAF V600E/MLH1 methylation then germline pathway as indicated
MSH2/MSH6 loss MSH2 or EPCAM germline/somatic alteration Germline evaluation; tumor sequencing if negative
Isolated MSH6 loss MSH6 alteration Germline evaluation
Isolated PMS2 loss PMS2 alteration or technical artifact Confirm and evaluate germline PMS2
MSI-high with intact IHC Nontruncating alteration or assay discordance Repeat/orthogonal testing and review

In a meta-analysis of 58,580 universally screened cancers, 6.22% were MMR-deficient and 2.00% carried a germline MMR pathogenic variant. IHC was missing in 11.81%, and germline testing occurred in only 76.30% of eligible patients (Eikenboom 2022, PMID 33887476).

Double-somatic MMR inactivation explains many “Lynch-like” tumors after negative germline testing. It changes relatives’ risk, but only after technically complete germline and tumor resolution.

Surveillance and prevention

Colonoscopy is the core preventive intervention because cancers can arise rapidly and flat lesions may be difficult to detect. Recommended start ages and intervals vary by gene and guideline; high-quality complete examination matters as much as nominal interval (Monahan 2020, PMID 31780574).

Surveillance reduces mortality but does not eliminate colorectal cancer. Prospective data show substantial survival after surveillance-detected cancers while documenting residual gene-specific incidence (Dominguez-Valentin 2023, PMID 37181409; Seppälä 2021, PMID 32507935).

CAPP2 randomized 600 mg aspirin daily versus placebo in 861 Lynch carriers. At 10-year follow-up, intention-to-treat colorectal-cancer incidence was lower after a delayed effect; adverse-event reporting during intervention did not show a major difference, but contemporary dose–benefit–bleeding tradeoffs remain central (Burn 2020, PMID 32534647). Resistant starch did not reduce Lynch-associated colorectal cancer in planned long follow-up, although an extracolonic signal was reported (Mathers 2022, PMID 35878732).

Surgery

Segmental versus extended colectomy balances metachronous-cancer prevention against bowel function, age, gene, comorbidity and surveillance feasibility. A germline result before surgery can therefore change operative extent.

Rectal-cancer surgery in Lynch must consider remaining colon risk; prophylactic gynecologic surgery is a separate, preference-sensitive discussion for relevant carriers. No single operation fits every MMR gene.

APC-associated familial adenomatous polyposis

Classic FAP is an autosomal-dominant APC syndrome with hundreds to thousands of colorectal adenomas and near-certain cancer risk without preventive management. Attenuated FAP presents with fewer, often proximal adenomas and later cancer (Half 2009, PMID 19822006; Galiatsatos 2006, PMID 16454848).

Domain Major manifestation Management problem
Colorectum Extensive adenomas and cancer Timing/type of prophylactic surgery
Duodenum/ampulla Adenomas and cancer Spigelman-stage surveillance and intervention
Stomach Fundic gland polyps and adenomas Geographic/phenotypic variation
Desmoid disease Mesenteric/abdominal fibromatosis Surgery can precipitate; morbidity may exceed cancer risk
Thyroid Papillary carcinoma risk Surveillance strategy varies
Children Hepatoblastoma signal Pediatric counseling, limited absolute risk

Management begins with endoscopic phenotype, APC testing and family assessment. Surveillance does not make indefinite retention of a carpeted colon safe; colectomy timing reflects polyp burden, dysplasia, symptoms, cancer and ability to survey (Aihara 2014, PMID 24161962).

Surgical options

Operation Advantage Long-term burden
Colectomy with ileorectal anastomosis Better bowel function; avoids pouch Rectal adenoma/cancer surveillance remains
Proctocolectomy with ileal pouch–anal anastomosis Removes colorectal mucosa more completely Pouch function, fertility and pouch/anal-transition surveillance
Proctocolectomy with end ileostomy Removes colorectal mucosa; avoids pouch failure Permanent stoma

Choice depends on rectal burden, cancer, genotype/phenotype, desmoid risk, age and preference. Surgical treatment is preventive, not curative of extracolonic FAP (Tudyka 2012, PMID 24714154).

Attenuated FAP can be missed when family size is small or a de novo variant occurs. Review literature reports later presentation and fewer polyps but substantial colorectal risk (Knudsen 2003, PMID 14574166).

MUTYH-associated polyposis

MUTYH-associated polyposis is usually autosomal recessive and arises from defective base-excision repair. Biallelic carriers can resemble attenuated FAP or present with cancer and few polyps; monoallelic risk is much smaller and family-history dependent.

The recessive pattern means affected siblings may occur without affected parents. Testing must distinguish one versus two pathogenic variants and, when phase matters, establish whether variants are on opposite alleles. Broad hereditary-GI guidelines include MUTYH alongside APC rather than using adenoma count alone (Syngal 2015, PMID 25645574).

Polymerase proofreading-associated polyposis

Germline exonuclease-domain variants in POLE or POLD1 impair proofreading and create ultramutated tumors. Variant location and classification are critical; not every missense variant in either gene is pathogenic (Mur 2020, PMID 32792570).

International recommendations restrict pathogenic interpretation to functionally and clinically supported exonuclease-domain variants (Mur 2023, PMID 37848928). Reported carrier cohorts support elevated colorectal risk but remain much smaller than Lynch/FAP datasets (Buchanan 2018, PMID 29120461).

Hamartomatous polyposis syndromes

Syndrome Gene(s) Hallmark Colorectal implication
Peutz–Jeghers STK11 Mucocutaneous pigmentation, small-bowel hamartomas Multiorgan cancer surveillance
Juvenile polyposis SMAD4, BMPR1A Multiple juvenile polyps Colorectal/gastric surveillance; SMAD4 may overlap HHT
PTEN hamartoma tumor syndrome PTEN Macrocephaly, mucocutaneous and multiorgan findings Colon surveillance within broader syndrome

These syndromes are rare and phenotypically variable. Pathology plus extraintestinal features should trigger genetics rather than a polyp-count threshold alone (Aretz 2010, PMID 20358032). Historical and contemporary guidance both emphasize multiorgan surveillance (Dunlop 2002, PMID 12221036; Syngal 2015, PMID 25645574).

Broad germline testing

Study Population Pathogenic finding Key caveat
Uson 2022 361 unselected CRC patients 15.5%; 9.4% incremental actionable findings Predominantly White tertiary-center cohort (PMID 33857637)
Coughlin 2022 34,244 commercial-panel patients 14.2% any PGV; 9.1% CRC/polyposis gene; 38.2% VUS Referral/commercial selection (PMID 36370464)
Ohio initiative 3,310 resected CRC patients 7.1% PGV among a tiered-testing pathway Not every participant received full panel (Pearlman 2021, PMID 34250417)
Universal-testing analysis Multigene strategy Actionable variants beyond criteria Panel optimization and age limits unresolved (Jiang 2022, PMID 33563768)

Broad panels increase yield but also VUS, incidental findings and genes with uncertain penetrance. A VUS is not a positive result and should not drive prophylactic surgery.

Cascade testing

Cascade testing converts one diagnosis into prevention for relatives, but uptake is low. In the prospective unselected cohort, only 16% of relatives completed family variant testing during follow-up (Uson 2022, PMID 33857637).

Barriers include communication burden placed on the patient, cost, geography, privacy concerns, limited counseling and relatives’ different health systems. A 2025 Swedish randomized trial across Lynch syndrome and hereditary breast/ovarian cancer families found genetic-counselling uptake of 71% with an offer of direct letters versus 67% with family-mediated disclosure alone (adjusted OR 1.24, 95% CI 0.79–1.95); this did not establish superiority and may not generalize to lower-uptake systems (Ehrencrona 2025, PMID 40745491). Direct-contact and digital tools therefore require consent, jurisdiction-specific governance and context-specific testing.

Variants and uncertainty

Result Meaning Appropriate action
Pathogenic/likely pathogenic Evidence supports disease causation Syndrome-specific management and cascade testing
VUS Evidence insufficient Do not use as if pathogenic; periodically re-evaluate
Negative, informative family variant known Familial variant absent Return to risk based on remaining history
Negative, no family variant known No tested cause found Family/phenotype risk may remain
Mosaic finding Variant present in subset of cells Confirm tissue distribution and transmission risk

Variant classification changes with population data, functional evidence and segregation. Ancestry imbalance in reference databases contributes to higher VUS rates in underrepresented groups (Coughlin 2022, PMID 36370464).

Historical perspective

Clinical descriptions of hereditary nonpolyposis colorectal cancer predated gene discovery and emphasized vertical transmission, young cancer and extracolonic tumors (Lynch 1997, PMID 9062584; Lynch 1999, PMID 10544223). Molecular testing transformed that phenotype into gene-specific syndromes but did not eliminate ascertainment bias.

Management guidelines have likewise moved from syndrome-level schedules toward gene- and phenotype-sensitive recommendations (Monahan 2020, PMID 31780574). Superseded advice remains important when interpreting older cohorts whose surveillance intensity differed.

Open questions

  • Should germline multigene testing be universal at colorectal-cancer diagnosis, and which minimum panel maximizes net benefit? (Uson 2022, PMID 33857637)
  • What colonoscopy interval is optimal for each MMR gene under modern high-quality examination? (Seppälä 2021, PMID 32507935)
  • Which aspirin dose and duration maximize Lynch prevention while minimizing bleeding? (Burn 2020, PMID 32534647)
  • Which cascade intervention improves completion in lower-uptake settings, given a Swedish direct-letter offer did not outperform family-mediated disclosure? (Ehrencrona 2025, PMID 40745491)
  • Which POLE/POLD1 variants truly confer high penetrance and require intensive surveillance? (Mur 2023, PMID 37848928)
  • How should ancestry-related VUS inequality be measured and reduced? (Coughlin 2022, PMID 36370464)

References

  1. Pearlman R, et al. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precis Oncol. 2021;5. PMID 34250417
  2. Uson PLS, et al. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2022;20(3):e508-e528. PMID 33857637
  3. Coughlin SE, et al. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer. JCO Precis Oncol. 2022;6:e2200517. PMID 36370464
  4. Peltomäki P, et al. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023;164(5):783-799. PMID 36706841
  5. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. PMID 19822006
  6. Møller P, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464-472. PMID 26657901
  7. Dominguez-Valentin M, et al. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database. EClinicalMedicine. 2023;58:101909. PMID 37181409
  8. Eikenboom EL, et al. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. Clin Gastroenterol Hepatol. 2022;20(3):e496-e507. PMID 33887476
  9. Monahan KJ, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411-444. PMID 31780574
  10. Seppälä TT, et al. Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD). Fam Cancer. 2021;20(1):35-39. PMID 32507935
  11. Burn J, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855-1863. PMID 32534647
  12. Mathers JC, et al. Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. Cancer Prev Res (Phila). 2022;15(9):623-634. PMID 35878732
  13. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385-98. PMID 16454848
  14. Aihara H, Kumar N, Thompson CC. Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: rationale and update. Eur J Gastroenterol Hepatol. 2014;26(3):255-62. PMID 24161962
  15. Tudyka VN, Clark SK. Surgical treatment in familial adenomatous polyposis. Ann Gastroenterol. 2012;25(3):201-206. PMID 24714154
  16. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer. 2003;2(1):43-55. PMID 14574166
  17. Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-62; quiz 263. PMID 25645574
  18. Mur P, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020;22(12):2089-2100. PMID 32792570
  19. Mur P, et al. Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1. Genome Med. 2023;15(1):85. PMID 37848928
  20. Buchanan DD, et al. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med. 2018;20(8):890-895. PMID 29120461
  21. Aretz S. The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. Dtsch Arztebl Int. 2010;107(10):163-73. PMID 20358032
  22. Dunlop MG, British Society for Gastroenterology, Association of Coloproctology for Great Britain and Ireland. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut. 2002;51 Suppl 5(Suppl 5):V21-7. PMID 12221036
  23. Jiang W, et al. Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. J Med Genet. 2022;59(4):370-376. PMID 33563768
  24. Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet. 1997;93(1):84-99. PMID 9062584
  25. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36(11):801-18. PMID 10544223
  26. Ehrencrona H, et al. Direct letters to relatives at risk of hereditary cancer-a randomised trial on healthcare-assisted versus family-mediated risk disclosure. Eur J Hum Genet. 2025;33(10):1359-1367. PMID 40745491